StockNews.AI
MTVA
StockNews.AI
76 days

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

1. MetaVia's DA-1241 pre-clinical data presented at ADA 2025 conference. 2. DA-1241 shows beneficial effects on metabolism and liver health. 3. Positive clinical trial results highlight DA-1241's potential for MASH and T2D. 4. DA-1241 promotes release of peptides aiding in glucose and lipid metabolism. 5. MetaVia also developing DA-1726 for obesity treatment with promising results.

6m saved
Insight
Article

FAQ

Why Bullish?

Positive pre-clinical data and acknowledgment at a major conference boosts investor confidence, similar to past biotechnology advancements that surged stock prices after positive clinical results.

How important is it?

The announced presentation and positive data strongly indicate future product viability, crucial for a clinical-stage biotechnology company.

Why Long Term?

The presentation prepares for future trials and product launch, potentially increasing demand and stock value over time as further positive results are expected.

Related Companies

DA-1241DA-1726
, /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting pre-clinical data on DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, has been accepted for a poster presentation at the American Diabetes Association's 85th Scientific Sessions, taking place June 20-23, 2025 at the McCormick Place Convention Center in Chicago, Illinois. Title: Additive Hepatoprotective Effects of DA-1241, a GPR119 Agonist, in Combination with Efruxifermin in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH Presenting Author: Yuna Chae, Lead Research Scientist, Dong-A ST Research Center Abstract Control Number: 2025-LB-6450 Session: 22-C Integrated Physiology—Liver Presentation Date: Sunday, June 22, 2025 Presentation Time: 12:30-1:30 pm CT A copy of the poster will be available on the Posters section of the MetaVia website after the presentation. Additionally, the poster will be published online on the journal, Diabetes®, website. About DA-1241DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. DA-1241 has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of MASH and T2D where DA-1241 reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects. About MetaViaMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects. For more information, please visit www.metaviatx.com. Contacts: MetaViaMarshall H. WoodworthChief Financial Officer+1-857-299-1033[email protected] Rx Communications GroupMichael Miller+1-917-633-6086[email protected] SOURCE MetaVia Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News